StockStory backs Astrana Health (ASTH), flags DaVita (DVA) and HASI despite analyst upside

StockStory said on May 13, 2026, that Astrana Health (NASDAQ: ASTH) deserves a second look, while DaVita (NYSE: DVA) and HA Sustainable Infrastructure Capital (NYSE: HASI) remain less compelling despite Wall Street price targets implying mixed returns. DaVita traded at $197.65, above its $185.57 consensus price target, implying a 6.1% downside. The dialysis-center operator was valued at 12.8 times forward earnings. HASI traded at $41.93, with a $47.87 consensus target implying 14.2% upside and a 14.3 times forward price-to-earnings ratio. Astrana Health traded at $37.86, below its $42.44 consensus target, implying 12.1% upside. The company, formerly Apollo Medical Holdings, was valued at 12 times forward earnings. StockStory cited Astrana’s technology-enabled physician platform and value-based care exposure as reasons for a more constructive view.